MedTrace Logo

Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events

NCT05085665 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2022-09-29

Study results available
· View outcomes & findings →

Summary

This study seeks to determine which Loa loa antigens are released into circulation when infected individuals are treated with ivermectin.

Conditions

  • Loiasis

Interventions

DRUG

Ivermectin

single dose, 150 ug/kg

Sponsors & Collaborators

  • Center for Research on Filariasis and Other Tropical Diseases, Cameroon

    collaborator OTHER

  • Washington University School of Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-30
Primary Completion
2021-08-31
Completion
2021-09-30
FDA Drug
Yes

Countries

  • Cameroon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05085665 on ClinicalTrials.gov